vs
Side-by-side financial comparison of Ovintiv Inc. (OVV) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.1B, roughly 1.2× Ovintiv Inc.). Ovintiv Inc. runs the higher net margin — 46.1% vs 25.3%, a 20.8% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -6.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $489.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -7.2%).
Ovintiv Inc. is a U.S. petroleum company based in Denver. The company was formed in 2020 through a restructuring of its Canadian predecessor, Encana.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
OVV vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $2.4B |
| Net Profit | $946.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 21.2% | 31.9% |
| Net Margin | 46.1% | 25.3% |
| Revenue YoY | -6.0% | 3.0% |
| Net Profit YoY | 1676.7% | 3.8% |
| EPS (diluted) | $3.64 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.1B | $2.4B | ||
| Q3 25 | $2.0B | $2.4B | ||
| Q2 25 | $2.2B | $2.5B | ||
| Q1 25 | $2.4B | $2.2B | ||
| Q4 24 | $2.2B | $2.3B | ||
| Q3 24 | $2.2B | $2.4B | ||
| Q2 24 | $2.2B | $2.4B | ||
| Q1 24 | $2.4B | $2.2B |
| Q4 25 | $946.0M | $603.0M | ||
| Q3 25 | $148.0M | $721.0M | ||
| Q2 25 | $307.0M | $718.0M | ||
| Q1 25 | $-159.0M | $631.0M | ||
| Q4 24 | $-60.0M | $581.0M | ||
| Q3 24 | $507.0M | $682.0M | ||
| Q2 24 | $340.0M | $624.0M | ||
| Q1 24 | $338.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 21.2% | 31.9% | ||
| Q3 25 | 13.5% | 37.0% | ||
| Q2 25 | 23.1% | 36.7% | ||
| Q1 25 | -3.7% | 36.5% | ||
| Q4 24 | 0.1% | 31.6% | ||
| Q3 24 | 24.2% | 36.6% | ||
| Q2 24 | 25.4% | 33.0% | ||
| Q1 24 | 20.7% | 34.1% |
| Q4 25 | 46.1% | 25.3% | ||
| Q3 25 | 7.3% | 30.0% | ||
| Q2 25 | 13.9% | 29.2% | ||
| Q1 25 | -6.7% | 28.4% | ||
| Q4 24 | -2.7% | 25.1% | ||
| Q3 24 | 23.3% | 28.6% | ||
| Q2 24 | 15.5% | 26.4% | ||
| Q1 24 | 14.2% | 27.4% |
| Q4 25 | $3.64 | $1.37 | ||
| Q3 25 | $0.57 | $1.63 | ||
| Q2 25 | $1.18 | $1.61 | ||
| Q1 25 | $-0.61 | $1.41 | ||
| Q4 24 | $-0.22 | $1.29 | ||
| Q3 24 | $1.92 | $1.50 | ||
| Q2 24 | $1.27 | $1.37 | ||
| Q1 24 | $1.24 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $280.0M | — |
| Total DebtLower is stronger | $5.2B | — |
| Stockholders' EquityBook value | $11.2B | $3.3B |
| Total Assets | $20.4B | $15.5B |
| Debt / EquityLower = less leverage | 0.46× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $280.0M | — | ||
| Q3 25 | $25.0M | $2.1B | ||
| Q2 25 | $20.0M | $1.4B | ||
| Q1 25 | $8.0M | $1.7B | ||
| Q4 24 | $42.0M | $2.0B | ||
| Q3 24 | $9.0M | $1.7B | ||
| Q2 24 | $8.0M | $1.6B | ||
| Q1 24 | $5.0M | $2.0B |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.2B | — | ||
| Q2 25 | $5.3B | — | ||
| Q1 25 | $5.5B | — | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | $5.9B | — | ||
| Q2 24 | $6.1B | — | ||
| Q1 24 | $6.2B | — |
| Q4 25 | $11.2B | $3.3B | ||
| Q3 25 | $10.2B | $5.4B | ||
| Q2 25 | $10.4B | $5.0B | ||
| Q1 25 | $10.1B | $4.7B | ||
| Q4 24 | $10.3B | $4.8B | ||
| Q3 24 | $10.7B | $5.2B | ||
| Q2 24 | $10.3B | $5.0B | ||
| Q1 24 | $10.3B | $5.1B |
| Q4 25 | $20.4B | $15.5B | ||
| Q3 25 | $19.4B | $15.2B | ||
| Q2 25 | $19.7B | $14.5B | ||
| Q1 25 | $19.6B | $14.1B | ||
| Q4 24 | $19.3B | $14.2B | ||
| Q3 24 | $19.9B | $14.4B | ||
| Q2 24 | $19.8B | $14.2B | ||
| Q1 24 | $19.8B | $14.3B |
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.55× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.60× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $954.0M | $893.0M |
| Free Cash FlowOCF − Capex | $489.0M | $732.0M |
| FCF MarginFCF / Revenue | 23.8% | 30.7% |
| Capex IntensityCapex / Revenue | 22.6% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.01× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $954.0M | $893.0M | ||
| Q3 25 | $812.0M | $938.0M | ||
| Q2 25 | $1.0B | $486.0M | ||
| Q1 25 | $873.0M | $587.0M | ||
| Q4 24 | $1.0B | $905.0M | ||
| Q3 24 | $1.0B | $951.0M | ||
| Q2 24 | $1.0B | $502.0M | ||
| Q1 24 | $659.0M | $595.0M |
| Q4 25 | $489.0M | $732.0M | ||
| Q3 25 | $268.0M | $805.0M | ||
| Q2 25 | $492.0M | $308.0M | ||
| Q1 25 | $256.0M | $438.0M | ||
| Q4 24 | $468.0M | $689.0M | ||
| Q3 24 | $484.0M | $784.0M | ||
| Q2 24 | $398.0M | $370.0M | ||
| Q1 24 | $68.0M | $455.0M |
| Q4 25 | 23.8% | 30.7% | ||
| Q3 25 | 13.3% | 33.5% | ||
| Q2 25 | 22.2% | 12.5% | ||
| Q1 25 | 10.8% | 19.7% | ||
| Q4 24 | 21.4% | 29.7% | ||
| Q3 24 | 22.2% | 32.8% | ||
| Q2 24 | 18.1% | 15.7% | ||
| Q1 24 | 2.8% | 20.8% |
| Q4 25 | 22.6% | 6.7% | ||
| Q3 25 | 26.9% | 5.5% | ||
| Q2 25 | 23.5% | 7.2% | ||
| Q1 25 | 26.0% | 6.7% | ||
| Q4 24 | 25.3% | 9.3% | ||
| Q3 24 | 24.7% | 7.0% | ||
| Q2 24 | 28.4% | 5.6% | ||
| Q1 24 | 24.8% | 6.4% |
| Q4 25 | 1.01× | 1.48× | ||
| Q3 25 | 5.49× | 1.30× | ||
| Q2 25 | 3.30× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 2.02× | 1.39× | ||
| Q2 24 | 3.00× | 0.80× | ||
| Q1 24 | 1.95× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OVV
| Product And Service Revenue | $1.7B | 84% |
| Sales Of Purchased Product | $338.0M | 16% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
